Kyntra Bio (KYNB) Debt Ratio (2023 - 2026)

Kyntra Bio (KYNB) posted Debt Ratio of 0.41 for Q2 2025, down 6.82% sequentially from 0.44 in Q1 2025, and up 67.52% YoY from 0.25 in Q2 2024.

Kyntra Bio (KYNB) Debt Ratio (2023 - 2026) Analysis & Trends

Kyntra Bio has reported Debt Ratio for 3 years, with the latest figure at 0.41 in Q2 2025.

Quarterly Debt Ratio rose 67.52% year-over-year to 0.41 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 0.41 (up 67.52% YoY) and the FY2024 annual result came in at 0.34, up 100.6% from the prior year.
Debt Ratio declined to 0.41 in Q2 2025 per KYNB's latest filing, from 0.44 in the prior quarter.
Over five years, Debt Ratio peaked at 0.44 in Q1 2025 and troughed at 0.14 in Q2 2023.
A 3-year average of 0.26 and a median of 0.25 in 2024 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 125.15% in 2025, down 67.52% in 2025.
Over 3 years, Debt Ratio stood at 0.17 in 2023, then soared by 100.6% to 0.34 in 2024, then grew by 21.54% to 0.41 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.41, 0.44, and 0.34 for Q2 2025, Q1 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn	-
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn	0.05
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn	-
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn	0.26
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn	0.03
9	Royalty Pharma	27.12 Bn	26.28 Bn	-	0.47
10	Kyntra Bio	28.95 Mn	50.43 Mn	1.47 Mn	0.19

Download Data